JonesTrading Downgrades Deciphera Pharmaceuticals to Hold, Announces $25.6 Price Target
Portfolio Pulse from Benzinga Newsdesk
JonesTrading analyst Soumit Roy downgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Buy to Hold and sets a price target of $25.6.

April 29, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Deciphera Pharmaceuticals downgraded by JonesTrading from Buy to Hold with a $25.6 price target.
The downgrade from Buy to Hold by a notable analyst could lead to a negative short-term sentiment among investors, potentially causing a decrease in stock price. The setting of a specific price target provides a benchmark that might influence investor expectations and market perception of the stock's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100